Kura Oncology announced that the first patients have been dosed in its KOMET-001 Phase 2 registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukemia, AML. "Dosing the first patients in our registration-directed trial of ziftomenib marks a significant milestone for our menin inhibitor program," said Troy Wilson, Ph.D., J.D., President & Chief Executive Officer of Kura Oncology. "Building on the strength of our Phase 1 data, we remain committed to our mission to realize the full potential of ziftomenib as an important treatment option to patients with acute leukemia. The speed with which we have begun enrolling in this registration-enabling Phase 2 study speaks to the significant interest in ziftomenib among investigators."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KURA:
- Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
- Kura Oncology to Participate in SVB Securities Global Biopharma Conference
- 2 “Strong Buy” Small Cap Stocks That Can Rip Higher in 2023
- Kura Oncology initiated with a Buy at Stifel
- Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor